TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH ist ein biopharmazeutisches Forschungsinstitut, das neue Diagnostika und Arzneimittel für die Therapie von Krebs und anderen Erkrankungen mit hohem medizinischem Bedarf entwickelt. Der Schwerpunkt von TRON liegt in der Entwicklung neuer Plattformen für personalisierte Therapiekonzepte und Biomarker, und somit in der Überführung grundlagenorientierter Forschung in die Entwicklung neuer Arzneimittel. In Zusammenarbeit mit akademischen Institutionen, Biotechnologiefirmen und der pharmazeutischen Industrie kommen in der Forschung am TRON modernste Technologien zum Einsatz. Zudem stellt TRON seine einzigartige Expertise und Infrastruktur der Entwicklung von innovativen Arzneimitteln zur besseren Patientenversorgung zur Verfügung.

Spotlight

Vertical Smart Slide 1
TRON at CIMT2016
TRON at CIMT2016
Posted 2 Wochen ago

Mainz, 10 - 12 May 2016 – TRON at CIMT 2016
“Mechanisms of Efficacy in Cancer Immunotherapy”
Looking forward to the 2016 Annual Meeting of Cancer Immunotherapy in Mainz. Connect with us at booth A021 or at any of our posters.

more information

Review by TRON/BioNT…
TRON Review in Clinical Cancer Research
Posted 1 Monat ago

Mainz, April 2016 – Review in CCR Focus "Opportunities and Challenges in Cancer Immunotherapy":
“Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines”
TRON and BioNTech scientists have written an overview of the clinical development of individualized neoepitope cancer vaccines, which is published now as CCR Focus Review article in Clinical Cancer Research.

more information

Prof. Peer from the …
TRON / BioNTech in Nature Medicine News
Posted 3 Monaten ago

Mainz, February 2016
TRON/BioNTech in Nature Medicine News Feature:
“Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment”
TRONs efforts to develop individualized cancer vaccines based on tumor-specific mutations is covered in a recent News Feature published in Nature Medicine.
For more information please click the Link below, which will direct you to the Nature Medicine website featuring the article.

more information

Prof. Peer from the …
Prof. Peer from the Tel Aviv University (TAU), Israel, visiting TRON
Posted 7 Monaten ago

Mainz, October 2015 – TRON Seminar in Translational Oncology
“RNA Therapeutics : New Era in Personalized Medicine?” 
Prof. Dan Peer, PhD - Department of Cell Research and Immunology, Tel Aviv University (TAU), Israel
5 PM, Lecture Hall Building 708, University Medical Center Mainz
Langenbeckstr. 1, 55131 Mainz, Germany

more information

Prof. Schoenberger f…
Prof. Schoenberger from the La Jolla Institute for Allergy and Immunology visiting TRON
Posted 10 Monaten ago

Mainz, July 2015 – TRON has the honor to host visiting Prof. Stephen Schoenberger at its facilities to promote international scientific interactions and facilitate collaborations in the fields of Immunology and Immunotherapy. Prof Schoenberger is co-author on a recent publication in Nature by TRON scientists focusing on mutated epitopes in cancer.  During his time at TRON Prof. Schoenberger will interact with different scientific teams and delve deeper into the various scientific challenges of individualized cancer vaccine research.

more information

Besuch einer Delegat…
Besuch einer Delegation aus dem Sultanat Oman im TRON
Posted 11 Monaten ago

Mainz, June 2015 – On June 1st and with generous support of the Ministry of Economics of Rhineland Palatinate, TRON welcomed a high-ranking delegation from the Sultanate of Oman for discussions on tasks and results of previous scientific works at TRON. Prof. Dr. Ulrich Förstermann of the Mainz University Medical Center also took part in the discussions.

more information

TRON is part of the …
TRON is part of the Cancer Research Consortium “Immuno-Transporter” to collaborate to develop innovative appro…
Posted 12 Monaten ago

Mainz, June, 2015 – The consortium partners will jointly develop methods to achieve tumor-specific activation of a patient's immune system to make it recognize, target and fight cancer
The newly established "IMMUNO-TRANSPORTER" consortium will collaborate to develop innovative approaches in the field of cancer immunotherapy. 

more information

TRON is part of the …
TRON is part of the European Bioinformatics Research Consortium on personalised cancer immunotherapy
Posted 12 Monaten ago

Mainz, May 1, 2015 – Experts in bioinformatics and cancer immunology to develop an Advanced bioinformatics platform for personalised cancer immunotherapyOn May 1st, TRON under the leadership of Prof. Dr. med. Ugur Sahin started an innovative research project on personalised cancer immunotherapy.

more information

Auf dem Weg zu einer…
Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
Posted 1 Jahr ago

Mainz, April 23, 2015 – Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
Neue immunologische Erkenntnisse und technologische Fortschritte ebnen den Weg für maßgeschneiderte Krebsimpfstoffe / klinische Studie läuft bereits

more information

Medizin des 21. Jahr…
Call for Papers: RNA Vaccination Therapy
Posted 1 Jahr ago

Mainz, 28. Februar 2015 – TRON IDC Leitung als Editoren einer Sonderausgabe des Journal of Immunology Research
Auf dem Gebiet der therapeutischen Impfung gegen Krebs hat die in vitro transkribierte synthetische mRNA (IVT RNA) in den letzten Jahren großes Interesse als innovatives Arzneimittelformat geweckt, das sich auch auf die Bereiche der antiviralen Impfstoffe übertragen hat.

more information

News

Vertical Smart Slide 1
TRON Seminar in Tran…
Posted 1 Monat ago

Mainz, April 28 2016 “Exploiting Natural Killer cells for immunotherapy of cancer”, PD Dr. rer. nat. Adelheid Cerwenka from the German Cancer Research Center (DKFZ) is visiting TRON.

Prof. Hämmerling fro…
Posted 2 Monaten ago

Mainz, April 7 2016 “Regulation of tumor immunity by macrophage and eosinophils”, Prof. Günter Hämmerling from the German Cancer Research Center (DKFZ) is visiting TRON.

Vortrag auf dem Worl…
Posted 3 Monaten ago

Davos, März 16, 2016 - "Eliciting potent T-cells against individual mutant neoantigens – the mutanome as rich target source for individualized cancer vaccination" Vortrag von Dr. Sebastian Kreiter in der Session "Immune Tolerance" auf dem 10. World Immune Regulation Meeting Davos (CH).

Vortrag 32. Deutsche…
Posted 3 Monaten ago

Berlin, Februar 25, 2016 - "Neue Methoden zur Identifizierung von Tumorantigenen als Targets für Tumorvakzine" Vortrag von Mathias Vormehr in der Session "Translationale Onkologie" auf dem 32. Deutschen Krebskongress in Berlin.

Univ.-Prof. Dr. Dr. …
Posted 7 Monaten ago

Mainz, October 19, 2015Honor
Univ.-Prof. Dr. Dr. h.c. Christoph Huber receives Federal Cross of Merit 1st class